|
Acute Coronary Syndrome
|
0.020 |
Biomarker
|
disease |
BEFREE |
In cardiovascular medicine, however, chromogranin A measurement has only recently gained interest, since increased concentrations in the circulation are associated with risk of clinical worsening and death in patients with acute coronary syndromes or chronic heart failure.
|
24325234 |
2014 |
|
Acute Coronary Syndrome
|
0.020 |
Biomarker
|
disease |
BEFREE |
Plasma Catestatin in Patients with Acute Coronary Syndrome.
|
27681934 |
2018 |
|
Acute exacerbation of chronic obstructive airways disease
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Adjusting for established risk indices and biomarkers, circulating CgA levels were found to be associated with mortality in patients with acute HF, but not in patients with acute exacerbation of chronic obstructive pulmonary disease.
|
28209766 |
2017 |
|
Acute pulmonary embolism
|
0.010 |
Biomarker
|
disease |
BEFREE |
Catestatin prevents endothelial inflammation and promotes thrombus resolution in acute pulmonary embolism in mice.
|
31682263 |
2019 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The expression pattern of NeuroD was mostly concordant with that of synaptophysin and partly with chromogranin A, indicating that NeuroD serves as a good neuroendocrine marker in gastric adenocarcinomas.
|
14533935 |
2003 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Once a broad tumor class is established, more specific differentiation markers can be pursued (e.g., lineage-restricted transcription factors for adenocarcinoma; p40 for squamous cell carcinoma; chromogranin A and synaptophysin or INSM1 for neuroendocrine neoplasms).
|
31786484 |
2020 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
LHGDN |
Our unexpected finding that the neuroendocrine cell markers PGP 9.5 and ChA are expressed by PC-3 and DU145 cells, suggests that these cells may have been derived from metastatic adenocarcinomas which had undergone neuroendocrine differentiation or alternatively the expression occurred ectopically as a result of cell culture.
|
17929277 |
2007 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The SSP was developed in 68 NSCLC tumors of adenocarcinoma (AC), squamous cell carcinoma (SqCC) and large-cell neuroendocrine carcinoma (LCNEC) histology, based on NanoString expression of 11 (CHGA, SYP, CD56, SFTPG, NAPSA, TTF-1, TP73L, KRT6A, KRT5, KRT40, KRT16) relevant genes for IHC-based NSCLC histology classification.
|
30914778 |
2019 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Forced expression of the INSM1 gene in adenocarcinoma cell lines (H358 and H1975) induced the expression of ASCL1, brain-2 (BRN2), chromogranin A, synaptophysin, and neural cell adhesion molecule 1; in contrast, knockdown of the INSM1 gene by siRNA in SCLC (H69 and H889) decreased their expression.
|
26482608 |
2015 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition to variation in immunohistochemically determined phenotypic expression regarding alpha-fetoprotein, chromogranin A and estrogen receptors, the established cell lines showed varying differentiation (moderately or poorly differentiated adenocarcinoma, adenosquamous carcinoma and poorly differentiated adenocarcinoma with multinuclear giant cells and bone formation).
|
15016319 |
2004 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Biopsies from the anal canal tumor, swollen lymph node, and Paget lesion all showed poorly differentiated adenocarcinoma with neuroendocrine features expressing synaptophysin and chromogranin A. Serum CEA and NSE levels were high, 809.4 ng/ml and 85.8 ng/ml, respectively.
|
30458812 |
2018 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Recently, mixed forms between adenocarcinoma and neuroendocrine prostate cancer (NEPC) have emerged that are characterized by persistent androgen receptor (AR)-signalling and elevated chromogranin A (CgA) levels.
|
30337589 |
2018 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
LHGDN |
In the present study, the expression of common NE markers, i.e., chromogranin A (ChGA), serotonin (5HT), neuron-specific enolase (NSE) and adrenomedullin (AM), was retrospectively examined in formalin-fixed, paraffin-embedded prostate tissue samples obtained from patients with adenocarcinoma and from patients with nodular hyperplasia of the prostatic gland (NHPG) (33 and 28, respectively).
|
15462496 |
2004 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our unexpected finding that the neuroendocrine cell markers PGP 9.5 and ChA are expressed by PC-3 and DU145 cells, suggests that these cells may have been derived from metastatic adenocarcinomas which had undergone neuroendocrine differentiation or alternatively the expression occurred ectopically as a result of cell culture.
|
17929277 |
2007 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Chromogranin A and B and secretogranin II in prostatic adenocarcinomas: neuroendocrine expression in patients untreated and treated with androgen deprivation therapy.
|
9465942 |
1998 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Neuroendocrine-like trans-differentiation of prostate cancer adenocarcinomas correlates with serum levels of Chromogranin A (CgA) and drives treatment resistance.
|
31653712 |
2019 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, in three types of non-neurosecretory cells (CV-1, adenocarcinoma TS/A and a clone of PC12 incompetent for secretion) the transfected chromogranin A accumulated mostly in the Golgi/transGolgi area and was released rapidly from resting cells (constitutive secretion) as revealed by both immunofluorescence during cycloheximide treatment and pulse-chase experiments.
|
14734658 |
2004 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
To investigate the effect of CgA secretion on neoplastic morphogenesis and progression, we have transfected mouse RMA lymphoma and TS/A adenocarcinoma cells with the cDNA encoding human CgA and selected several CgA-positive (secreting) and CgA-negative (nonsecreting) clones.
|
11830555 |
2002 |
|
Adenocarcinoma of prostate
|
0.010 |
Biomarker
|
disease |
BEFREE |
Clinical understaging in patients with prostate adenocarcinoma submitted to radical prostatectomy: predictive value of serum chromogranin A.
|
14968443 |
2004 |
|
Adenoma
|
0.010 |
AlteredExpression
|
group |
BEFREE |
We studied the effects of GnRH, CRF, dexamethasone, and phorbol 12-myristate 13-acetate on FSH and LH secretion and on FSH beta and chromogranin-A and -B mRNA expression in 10 chromogranin-A-positive adenomas in vitro to analyze the regulation of FSH and chromogranin-A and -B expression in these neoplasms.
|
2118538 |
1990 |
|
Adrenal Cortical Adenoma
|
0.010 |
AlteredExpression
|
disease |
LHGDN |
We enrolled 19 patients (12 females and 7 males, mean+/-SD age 54.9+/-11.2 yr, age range 34-75 yr) with incidental, non-functioning, benign adrenocortical adenomas, and measured circulating levels of CgA, catecholamines and creatinine before and 2 months after surgery.
|
15648545 |
2004 |
|
Adrenal Gland Hyperfunction
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Tests for a neuroendocrine tumor were performed due to symptoms of hypercortisolemia and an elevated concentration of chromogranin A in the serum.
|
28477260 |
2017 |
|
Adrenal Gland Pheochromocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The change in chromogranin A plasma concentration after pheochromocytoma resection best fit a two-compartment model, with an initial rapid half-life time of 16 minutes, followed by a longer half-life time of 520 minutes.
|
2189303 |
1990 |
|
Adrenal Gland Pheochromocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have recently validated several assays for the measurement of peptides derived from chromogranin A (CgA) and secretogranin II (SgII) in order to determine whether these secreted neuroendocrine products could provide useful, complementary markers for the diagnosis and prognosis of PHEOs.
|
17102122 |
2006 |
|
Adrenal Gland Pheochromocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chromogranin A (CgA), which is a major protein in adrenal chromaffin cells and adrenergic neurons, is a clinically relevant endocrine and neuroendocrine tumor marker including pheochromocytomas, neuroblastomas, and related neurogenic tumors.
|
31682468 |
2020 |